Butenolide Synthesis from Functionalized Cyclopropenones
作者:Sean S. Nguyen、Andrew J. Ferreira、Zane G. Long、Tyler K. Heiss、Robert S. Dorn、R. David Row、Jennifer A. Prescher
DOI:10.1021/acs.orglett.9b03298
日期:2019.11.1
A general method to synthesize substituted butenolides from hydroxymethylcyclopropenones is reported. Functionalized cyclopropenones undergo ring-opening reactions with catalytic amounts of phosphine, forming reactive ketene ylides. These intermediates can be trapped by pendant hydroxy groups to afford target butenolide scaffolds. The reaction proceeds efficiently in diverse solvents and with low catalyst
HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME
申请人:Millennium Pharmaceuticals, Inc.
公开号:EP3016934B1
公开(公告)日:2018-01-10
HETEROARYL INHIBITORS OF SUMO ACTIVATING ENZYME
申请人:MILLENNIUM PHARMACEUTICALS, INC.
公开号:US20160355504A1
公开(公告)日:2016-12-08
Disclosed are compounds of formula (I); or a pharmaceutically acceptable salt thereof; wherein Y, Ra, Ra′, Rc, Rf, X2, Rd, Rd′, Re, Re′2, m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders.
US9695154B2
申请人:——
公开号:US9695154B2
公开(公告)日:2017-07-04
[EN] HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME<br/>[FR] COMPOSÉS HÉTÉROARYLIQUES POUVANT ÊTRE UTILISÉS EN TANT QU'INHIBITEURS DE L'ENZYME SAE
申请人:MILLENNIUM PHARM INC
公开号:WO2015002994A2
公开(公告)日:2015-01-08
Disclosed are compounds of formula (I): or a pharmaceutically acceptable salt thereof; wherein Y, Ra, Ra', Rc, Rf, X2, Rd, Rd', Re, Re', m, and G have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry, useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular and neurodegenerative diseases or disorders.